- Home
- VMD vs ATAI Comparison
VMD vs ATAI Comparison
Compare VMD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | ATAI |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.3M | 1.3B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VMD | ATAI |
|---|---|---|
| Price | $9.35 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.13 |
| AVG Volume (30 Days) | 357.9K | ★ 4.4M |
| Earning Date | 03-04-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $270,280,000.00 | $308,000.00 |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | ★ 20.52 | N/A |
| 52 Week Low | $5.93 | $1.15 |
| 52 Week High | $10.06 | $6.73 |
Technical Indicators
Market Signals| Indicator | VMD | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 41.37 |
| Support Level | $7.93 | $3.06 |
| Resistance Level | $10.06 | $4.30 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 50.35 | 13.33 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.